title: [Birth defects in a cohort of uninfected children born to HIV-infected women].
abstract: BACKGROUND
  Mother-to-Child HIV transmission is now just 1% in western countries, due to prevention measures. Antiretroviral Treatment (ART) drugs do have adverse effects, anaemia and myelosupression caused by cidovudina being the most commonly observed effects. In the present study, we have analysed the proportion and characteristics of congenital malformations (CM) or birth defects (BD) in a cohort of uninfected children born to HIV-infected women.
  
  
  METHODS
  A total of 623 uninfected children belonging to the FIPSE cohort were followed up according to standardised protocols. This cohort includes 8 public hospitals from Madrid and follows up HIV-infected pregnant women and their children. Children were classified according to prematurity, ethnic origin, birth weight, withdrawal syndrome, in-utero treatment. Birth defects were described and defined according to the EUROCAT, the European registry for BD. Mild errors of morphogenesis were excluded from the analysis. Categorical variables were compared with the X(2) or the Fisher test.
  
  
  RESULTS
  A total of 78% (486) of the mothers were of Caucasian origin; 18.8% (117) used some illicit drug (heroine, cocaine or methadone) during gestation; 51 mothers (8.1%) received no ART, 10 (1.6%) received monotherapy and 469 (75.3%) received HAART. BD were seen in 52 children, with the most frequent being genitourinary and cardiological. Anaemia in the first trimester was an associated risk for BD (17.9% vs. 8.1%, P = 0,04). Similarly, mothers who used any illicit drug (plus methadone), had a slightly higher risk for BD in their offspring (13.8% vs. 7.6%, P = 0,04) There was no increased risk for BD significantly associated with any of the in-utero used antiretrovirals, although Nevirapine use in-utero showed a protective effect. Children born to mothers who received ART in the first trimester had the same rate of BD (7.4%) as those whose mothers started ART in the second trimester (8.8%), P = 0,67.
  
  
  CONCLUSIONS
  The proportion of BD that we have observed seems higher than those shown in other European teratogenicity studies and also higher than those shown in cohorts with HIV and antiretroviral exposed infants. This may be due to the fact that our series show the results of an active surveillance system (that includes ultrasound), where BD classically appear in a higher proportion. Immunovirological characteristics of the mother did not influence the proportion of BD, but anaemia in the fist trimester and the use of illicit drugs (or methadone) did. No specific antiretroviral drug was associated with an increase in BD, although Nevirapine showed a possible protective effect in the statistical analysis. Mothers who started antiretrovirals in the first trimester do not have more BD in their offspring than mothers who started on antiretrovirals later on.
authors.affiliation: Servicio de Pediatría, Hospital Universitario de Getafe, Madrid, España. mfndezibieta2@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Fernández Ibieta
authors.forename: J T
authors.initials: JT
authors.lastname: Ramos Amador
authors.forename: J M
authors.initials: JM
authors.lastname: Bellón Cano
authors.forename: M I
authors.initials: MI
authors.lastname: González-Tomé
authors.forename: S
authors.initials: S
authors.lastname: Guillén Martín
authors.forename: M
authors.initials: M
authors.lastname: Navarro Gómez
authors.forename: M I
authors.initials: MI
authors.lastname: de José
authors.forename: J
authors.initials: J
authors.lastname: Beceiro
authors.forename: E
authors.initials: E
authors.lastname: Iglesias
authors.forename: L
authors.initials: L
authors.lastname: Prieto
authors.forename: M J
authors.initials: MJ
authors.lastname: Santos
authors.forename: N
authors.initials: N
authors.lastname: Martínez Guardia
authors.forename: M A
authors.initials: MA
authors.lastname: Roa
authors.forename: J
authors.initials: J
authors.lastname: Regidor
mesh_terms: D002675:Child, Preschool; D000013:Congenital Abnormalities / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D011446:Prospective Studies